首页> 美国卫生研究院文献>Cardiology Research and Practice >Contrast-Induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention
【2h】

Contrast-Induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention

机译:经皮冠状动脉介入治疗患者的造影剂肾病

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Contrast Induced Nephropathy (CIN) is a feared complication of numerous radiological procedures that expose patients to contrast media. The most notorious of these procedures is percutaneous coronary intervention (PCI). Not only is this a leading cause of morbidity and mortality, but it also adds to increased costs in high risk patients undergoing PCI. It is thought to result from direct cytotoxicity and hemodynamic challenge to renal tissue. CIN is defined as an increase in serum creatinine by either ≥0.5 mg/dL or by ≥25% from baseline within the first 2-3 days after contrast administration, after other causes of renal impairment have been excluded. The incidence is considerably higher in diabetics, elderly and patients with pre-existing renal disease when compared to the general population. The nephrotoxic potential of various contrast agents must be evaluated completely, with prevention as the mainstay of focus as no effective treatment exists. The purpose of this article is to examine the pathophysiology, risk factors, and clinical course of CIN, as well as the most recent studies dealing with its prevention and potential therapeutic interventions, especially during PCI. The role of gadolinium as an alternative to iodinated contrast is also discussed.
机译:造影剂诱发的肾病(CIN)是使患者暴露于造影剂的众多放射学检查过程中令人担忧的并发症。这些程序中最臭名昭著的是经皮冠状动脉介入治疗(PCI)。这不仅是发病率和死亡率的主要原因,而且还增加了接受PCI的高危患者的治疗费用。据认为是由于直接的细胞毒性和对肾组织的血流动力学挑战所致。 CIN被定义为在对比剂施用后的最初2-3天内,血清肌酐比基线增加≥0.5μmg/ dL或≥25%,而排除了其他原因的肾脏损害。与一般人群相比,糖尿病患者,老年人和已有肾脏疾病的患者的发病率要高得多。必须对各种造影剂的肾毒性潜力进行全面评估,因为没有有效的治疗方法,因此以预防为重点。本文的目的是检查CIN的病理生理,危险因素和临床过程,以及有关其预防和潜在治疗干预措施(尤其是PCI期间)的最新研究。还讨论了lin替代碘对比剂的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号